Welcome to our Careers page!!
WHY WORK AT ALLIGATOR
Alligator is a science- and knowledge-based company whose success is built on the experience, expertise, commitment and creativity of its employees. We work towards our common goal of producing medicines to conquer cancer. Most of our employees are graduates and many have PhDs. Our business is located in Medicon Village in Lund where we have purpose-built laboratories and offices and can operate in a creative environment. We develop our employees’ skills through active knowledge-sharing in international networks and collaboration with academic institutions and multinational partners. All of this makes Alligator an exciting and dynamic place to work, running leading research and development projects in tumor-directed immunotherapy.
OPEN POSITIONS
OUR EMPLOYEES
Matthías Thórólfsson
Principal Scientist Protein Chemistry
Previously at Novo Nordisk, now Principal Scientist Protein Chemistry at Alligator: “Making the move from the biggest pharmaceutical company in Scandinavia to an innovative biotech company like Alligator has been incredibly stimulating. The short decision paths, with greater responsibility, increased visibility and more autonomy, are among many positive aspects. Alligator is expanding fast, with several drug candidates in preclinical and clinical development in the most exciting area of drug development. I bring a lot of experience and expertise in the development and production of antibodies, and it is a privilege to be part of the journey towards the goal of Alligator being one of the major players in immuno-oncology.”
ABOUT
Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.
CONTACT
Alligator Bioscience AB
Medicon Village
Scheelevägen 2
223 81 Lund
Sweden
Telefon: + 46 (0)46 540 82 00
SUBSCRIBE
Subscribe to get our pressreleases by email.